729 related articles for article (PubMed ID: 1988827)
1. Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. A randomized, double-blind, placebo-controlled trial. The HA-1A Sepsis Study Group.
Ziegler EJ; Fisher CJ; Sprung CL; Straube RC; Sadoff JC; Foulke GE; Wortel CH; Fink MP; Dellinger RP; Teng NN
N Engl J Med; 1991 Feb; 324(7):429-36. PubMed ID: 1988827
[TBL] [Abstract][Full Text] [Related]
2. The French National Registry of HA-1A (Centoxin) in septic shock. A cohort study of 600 patients. The National Committee for the Evaluation of Centoxin.
Arch Intern Med; 1994 Nov; 154(21):2484-91. PubMed ID: 7979845
[TBL] [Abstract][Full Text] [Related]
3. Gram-negative sepsis, the sepsis syndrome, and the role of antiendotoxin monoclonal antibodies.
Barriere SL; Guglielmo BJ
Clin Pharm; 1992 Mar; 11(3):223-35. PubMed ID: 1611812
[TBL] [Abstract][Full Text] [Related]
4. Projected impact of monoclonal anti-endotoxin antibody therapy.
Bates DW; Lee TH
Arch Intern Med; 1994 Jun; 154(11):1241-9. PubMed ID: 8203991
[TBL] [Abstract][Full Text] [Related]
5. Treatment of septic shock with human monoclonal antibody HA-1A. A randomized, double-blind, placebo-controlled trial. CHESS Trial Study Group.
McCloskey RV; Straube RC; Sanders C; Smith SM; Smith CR
Ann Intern Med; 1994 Jul; 121(1):1-5. PubMed ID: 8198341
[TBL] [Abstract][Full Text] [Related]
6. Randomized, placebo-controlled trial of HA-1A, a human monoclonal antibody to endotoxin, in children with meningococcal septic shock. European Pediatric Meningococcal Septic Shock Trial Study Group.
Derkx B; Wittes J; McCloskey R
Clin Infect Dis; 1999 Apr; 28(4):770-7. PubMed ID: 10825037
[TBL] [Abstract][Full Text] [Related]
7. Multicenter evaluation of a human monoclonal antibody to Enterobacteriaceae common antigen in patients with Gram-negative sepsis.
Albertson TE; Panacek EA; MacArthur RD; Johnson SB; Benjamin E; Matuschak GM; Zaloga G; Maki D; Silverstein J; Tobias JK; Haenftling K; Black G; Cowens JW;
Crit Care Med; 2003 Feb; 31(2):419-27. PubMed ID: 12576946
[TBL] [Abstract][Full Text] [Related]
8. A controlled clinical trial of E5 murine monoclonal IgM antibody to endotoxin in the treatment of gram-negative sepsis. The XOMA Sepsis Study Group.
Greenman RL; Schein RM; Martin MA; Wenzel RP; MacIntyre NR; Emmanuel G; Chmel H; Kohler RB; McCarthy M; Plouffe J
JAMA; 1991 Aug; 266(8):1097-102. PubMed ID: 1865542
[TBL] [Abstract][Full Text] [Related]
9. Anti-lipopolysaccharide and anti-tumor necrosis factor/cachectin antibodies for the treatment of gram-negative bacteremia and septic shock.
Calandra T; Baumgartner JD; Glauser MP
Prog Clin Biol Res; 1991; 367():141-59. PubMed ID: 1924424
[TBL] [Abstract][Full Text] [Related]
10. HA-1A. A human monoclonal antibody for the treatment of gram-negative sepsis.
Smith CR; Straube RC; Ziegler EJ
Infect Dis Clin North Am; 1992 Mar; 6(1):253-66. PubMed ID: 1578120
[TBL] [Abstract][Full Text] [Related]
11. Treatment of gram-negative bacteremia and shock with human antiserum to a mutant Escherichia coli.
Ziegler EJ; McCutchan JA; Fierer J; Glauser MP; Sadoff JC; Douglas H; Braude AI
N Engl J Med; 1982 Nov; 307(20):1225-30. PubMed ID: 6752708
[TBL] [Abstract][Full Text] [Related]
12. A controlled trial of HA-1A in a canine model of gram-negative septic shock.
Quezado ZM; Natanson C; Alling DW; Banks SM; Koev CA; Elin RJ; Hosseini JM; Bacher JD; Danner RL; Hoffman WD
JAMA; 1993 May; 269(17):2221-7. PubMed ID: 8474201
[TBL] [Abstract][Full Text] [Related]
13. Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein. The Soluble TNF Receptor Sepsis Study Group.
Fisher CJ; Agosti JM; Opal SM; Lowry SF; Balk RA; Sadoff JC; Abraham E; Schein RM; Benjamin E
N Engl J Med; 1996 Jun; 334(26):1697-702. PubMed ID: 8637514
[TBL] [Abstract][Full Text] [Related]
14. Comparison of the efficacy, safety, and therapeutic usage of HA-1A and E5 in the treatment of gram-negative sepsis.
Quintiliani R; Cooper B; Maderazo E; Nightingale C
Hosp Formul; 1992 Jan; 27(1):49-52, 54, 57-60. PubMed ID: 10116116
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of a phospholipid emulsion (GR270773) in Gram-negative severe sepsis: results of a phase II multicenter, randomized, placebo-controlled, dose-finding clinical trial.
Dellinger RP; Tomayko JF; Angus DC; Opal S; Cupo MA; McDermott S; Ducher A; Calandra T; Cohen J;
Crit Care Med; 2009 Nov; 37(11):2929-38. PubMed ID: 19770753
[TBL] [Abstract][Full Text] [Related]
16. An evaluation of the hemodynamic effects of HA-1A human monoclonal antibody.
Kett DH; Quartin AA; Sprung CL; Fisher CJ; Peña MA; Heard SO; Zimmerman JL; Albertson TE; Panacek EA; Eidelman LA
Crit Care Med; 1994 Aug; 22(8):1227-34. PubMed ID: 8045141
[TBL] [Abstract][Full Text] [Related]
17. The role of monoclonal antibodies in the management of gram-negative sepsis. Experience with the E5 antibody.
Gorelick KJ; Chmel H
Infect Dis Clin North Am; 1991 Dec; 5(4):899-913. PubMed ID: 1783775
[TBL] [Abstract][Full Text] [Related]
18. Monoclonal antibodies and the treatment of gram-negative bacteremia and shock.
Wolff SM
N Engl J Med; 1991 Feb; 324(7):486-8. PubMed ID: 1988835
[No Abstract] [Full Text] [Related]
19. Human monoclonal antibody HA-1A binds to endotoxin via an epitope in the lipid A domain of lipopolysaccharide.
Bogard WC; Siegel SA; Leone AO; Damiano E; Shealy DJ; Ely TM; Frederick B; Mascelli MA; Siegel RC; Machielse B
J Immunol; 1993 May; 150(10):4438-49. PubMed ID: 7683319
[TBL] [Abstract][Full Text] [Related]
20. [Immunotherapy using the anti-endotoxin antibody HA-1A (Centoxin) in patients with sepsis syndrome; fair results following protocol selection of patients].
Costongs LG; Speelman P; van Lieshout JJ; van Deventer SJ; Lubbers MJ; Schipper HG
Ned Tijdschr Geneeskd; 1993 Feb; 137(7):355-60. PubMed ID: 8437634
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
